Adaptive Biotechnologies Corp (NAS:ADPT)
$ 6.29 -0.15 (-2.33%) Market Cap: 950.41 Mil Enterprise Value: 791.33 Mil PE Ratio: 0 PB Ratio: 4.25 GF Score: 78/100

Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 09:30PM GMT
Release Date Price: $29.19 (-2.41%)
Tycho W. Peterson
JP Morgan Chase & Co, Research Division - Senior Analyst

Okay. Good afternoon. We're going to go ahead and get started. I'm Tycho Peterson from the life science team. It's my pleasure to introduce our next company this afternoon, Adaptive Biotechnologies. We'll do a breakout right after in the Olympic Room.

And with that, let me turn it over to Chad Robins.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Thanks, Tycho. I appreciate the introduction. I'm Chad Robbins. I'm the CEO and Cofounder of Adaptive Biotechnologies. My brother, Harlan, and I started Adaptive about a decade ago on the premise that if we could read and translate the genetics of the immune system, we could create clinical products to diagnose and treat disease. I remind you of the safe harbor.

We believe that the immune system represents the largest clinical applications of genomics. The reason for that is simple. It's because your immune system both detects and treats almost all diseases in the exact same way,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot